NASDAQ:CLRB

Cellectar Biosciences Stock Insider Trading

Healthcare > Biotechnology

Buy CLRB

*Your capital is at risk

$2.74

-0.230 (-7.74%)

At Close: Jun 02, 2026

Cellectar Biosciences Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 99.84. In total, the insiders bought 12.7M and sold 198 CLRB shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	99.84
● Buy	12.7M shares
● Sell	198 shares
99% Buy Activity Negligible or No Correlation
Buy Signal High Confidence May 07, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 99.84. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (99% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 14, 2025 Buy	Stock option (right to buy) A-Award	Caruso James V President And CEO	CEO / President	900 000 Value: $261.0K
Feb 14, 2025 Buy	Stock option (right to buy) A-Award	Chanan-khan Asher Director	Director	60 000 Value: $17.4K
Feb 14, 2025 Buy	Stock option (right to buy) A-Award	Driscoll Frederick W Director	Director	60 000 Value: $17.4K
Feb 14, 2025 Buy	Stock option (right to buy) A-Award	Kolean Chad J Chief Financial Officer	C-Suite Officer	290 000 Value: $84.1K
Feb 14, 2025 Buy	Stock option (right to buy) A-Award	Longcor Jarrod Chief Operating Officer	C-Suite Officer	500 000 Value: $145.0K
Feb 14, 2025 Buy	Stock option (right to buy) A-Award	Loren Stefan Director	Director	60 000 Value: $17.4K
Feb 14, 2025 Buy	Stock option (right to buy) A-Award	Neis John Director	Director	60 000 Value: $17.4K
Feb 14, 2025 Buy	Stock option (right to buy) A-Award	Swirsky Douglas J Director	Director	90 000 Value: $26.1K
Jan 10, 2025 Buy	Common Stock P-Purchase	Longcor Jarrod Chief Operating Officer	C-Suite Officer	30 000 Value: $8K
Jan 10, 2025 Buy	Common Stock P-Purchase	Longcor Jarrod Chief Operating Officer	C-Suite Officer	30 000 Value: $8K
Jun 14, 2024 Buy	Stock option (right to buy) A-Award	Longcor Jarrod Chief Operating Officer	C-Suite Officer	500 000 Value: $1.33M
Jun 14, 2024 Buy	Stock option (right to buy) A-Award	Caruso James V President And CEO	CEO / President	900 000 Value: $2.39M
Jun 14, 2024 Buy	Stock option (right to buy) A-Award	Kolean Chad J Chief Financial Officer	C-Suite Officer	290 000 Value: $768.5K
Jun 14, 2024 Buy	Stock option (right to buy) A-Award	Shustov Andrei Senior Vice President, Medical	CEO / President	260 000 Value: $689.0K
Jun 14, 2024 Buy	Stock option (right to buy) A-Award	Lea Darrell Shane Chief Commercial Officer	Officer	260 000 Value: $689.0K
Jun 14, 2024 Buy	Stock option (right to buy) A-Award	Loren Stefan Director	Director	60 000 Value: $154.8K
Jun 14, 2024 Buy	Stock option (right to buy) A-Award	Swirsky Douglas J Director	Director	90 000 Value: $232.2K
Jun 14, 2024 Buy	Stock option (right to buy) A-Award	Neis John Director	Director	60 000 Value: $154.8K
Jun 14, 2024 Buy	Stock option (right to buy) A-Award	Driscoll Frederick W Director	Director	60 000 Value: $154.8K
Jun 14, 2024 Buy	Stock option (right to buy) A-Award	Chanan-khan Asher Director	Director	60 000 Value: $154.8K
Jun 14, 2024 Buy	Stock option (right to buy) A-Award	Driscoll Frederick W Director	Director	60 000 Value: $154.8K
Jun 14, 2024 Buy	Stock option (right to buy) A-Award	Neis John Director	Director	60 000 Value: $154.8K
Jun 14, 2024 Buy	Stock option (right to buy) A-Award	Chanan-khan Asher Director	Director	60 000 Value: $154.8K
Jun 14, 2024 Buy	Stock option (right to buy) A-Award	Swirsky Douglas J Director	Director	90 000 Value: $232.2K
Jun 14, 2024 Buy	Stock option (right to buy) A-Award	Loren Stefan Director	Director	60 000 Value: $154.8K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CELLECTAR BIOSCIENCES

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients;...

Read Full Profile Here